By Kelly Cloonan
Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders.
Under the agreement, Crispr will make an upfront payment of $25 million in cash and $70 million in equity to Sirius Therapeutics, the companies said Monday.
The companies will jointly develop SRSD107 under an equally split cost and profit-sharing structure, they said. Crispr will lead commercialization in the U.S., while Sirius will be responsible for commercialization in China.
Crispr will also be able to nominate up to two siRNA targets for research and development, for which it would retain opt-in rights to lead commercialization, the companies said. Sirius will be eligible to receive milestone payments as well as tiered royalties in high single to low-double digits.
SRSD107 aims to selectively inhibit Factor XI, a driver of pathological thrombosis, in order to reduce thrombotic events and minimize the risk of bleeding. Two Phase 1 trials of the treatment have found it to be safe and well-tolerated, the companies said.
The collaboration expands Crispr's portfolio to develop a broader range of gene-based medicines in addition to its gene-editing programs, the companies said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 19, 2025 16:44 ET (20:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。